Last edition
News about "lower respiratory tract disease "
FDA to Review GSK's Application to Expand Arexvy RSV Vaccine Use
The US Food and Drug Administration (FDA) has accepted to review GlaxoSmithKline (GSK)'s application to expand the use of its RSV vaccine, Arexvy, to include adults aged 18–49 who are at increased risk.
Lower Respiratory Tract Disease | 16/07/2025 | By Dineshwori | 114
GSK Announces Positive Data for Arexvy (RSV) Vaccine
Arexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older, including those who are at increased risk due to certain underlying medical conditions.
Lower Respiratory Tract Disease | 10/10/2024 | By Aishwarya | 374
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy